SearchSkip to Search Results
- 1Bladder cancer
- 1Epigallocatechin gallate
- 1Hepatitis C virus
- 1Liver transplantation
Deletion of F4L (ribonucleotide reductase) in Vaccinia Virus Produces a Selective Oncolytic Virus and Promotes Anti-tumor Immunity with Superior Safety in Bladder CancerDownload
Overall recurrence of non-muscle-invasive bladder cancer (NMIBC) can be as high as 80% within 5 years of initial treatment. High-grade NMIBC has the greatest risk of recurrence and treatment for these patients includes surgery followed by intravesical therapy with the immunotherapeutic agent...
Delivery of STAT3 inhibitor cucurbitacins to tumor by polymeric nano-carriers : Implications in cancer chemo- and immunotherapyDownload
Signal Transducer and Activator of Transcription 3 (STAT3), a common oncogenic mediator, is constitutively activated in many types of human cancers and plays a critical role in tumor growth and cancer immune evasion. The focus of this dissertation is the delivery of STAT3 inhibitor cucurbitacins...
Novel Agents Inhibiting Hepatitis C Virus; Application to Prevention of Re-infection after Liver TransplantationDownload
Recurrent Hepatitis C virus infection drives inferior outcomes experienced by patients undergoing liver transplantation due to HCV-associated liver disease. Existing therapies exhibit increased toxicity, poor efficacy, and profound patient intolerability in the immediate transplantation period....